Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Innovative pan-tumor target strategy for CAR-T therapy: cancer-specific exons as novel targets for pediatric solid and brain tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2003-
    • الموضوع:
      Immunotherapy, Adoptive*/methods ; Brain Neoplasms*/therapy ; Brain Neoplasms*/genetics ; Brain Neoplasms*/immunology ; Exons*/genetics; Humans ; Child ; Receptors, Chimeric Antigen ; Molecular Targeted Therapy ; Neoplasms/therapy ; Neoplasms/genetics ; Neoplasms/immunology
    • نبذة مختصرة :
      Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved remarkable success in treating chemotherapy-refractory hematological malignancies. However, its efficacy in solid and brain tumors remains limited due to challenges such as insufficient target antigens, poor T-cell adaptability, inefficient tumor site trafficking, and the immunosuppressive tumor microenvironment. To address these challenges, Shaw and colleagues proposed an innovative strategy targeting cancer-specific exons (CSEs) in pediatric solid and brain tumors. Using RNA sequencing data from 16 tumor types, the study identified 157 highly tumor-specific targets, including both known and novel proteins. The researchers validated several targets, including FN1 and COL11A1, demonstrating their therapeutic potential in in vitro and in vivo models. The study's approach of integrating exon-level analysis with a broad search for extracellular matrix proteins offers a new frontier for CAR-T therapy, providing valuable insights for improving immunotherapy in pediatric solid tumors. Although promising, the study also highlights the need for further evaluation of tumor recurrence and CAR-T cell exhaustion. The identification of novel pan-tumor targets may revolutionize CAR-T therapy design and expand its application in pediatric cancer treatment.
      Competing Interests: Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors have read and agreed to the published version of the manuscript. Competing interests The authors declare that they have no competing interests.
      (© 2024. The Author(s).)
    • References:
      Cell Rep. 2021 Nov 23;37(8):110047. (PMID: 34818552)
      Nat Commun. 2024 May 3;15(1):3732. (PMID: 38702309)
      Front Immunol. 2022 Jun 10;13:927153. (PMID: 35757715)
      Front Immunol. 2018 Nov 08;9:2593. (PMID: 30467505)
      Front Oncol. 2012 Dec 17;2:194. (PMID: 23251904)
      Cell Mol Immunol. 2021 May;18(5):1085-1095. (PMID: 33785843)
      Cancer Discov. 2021 Mar;11(3):542-544. (PMID: 33589423)
      Mol Ther. 2020 Nov 4;28(11):2320-2339. (PMID: 32979309)
      Int J Mol Sci. 2020 Jan 14;21(2):. (PMID: 31947597)
      Theranostics. 2022 Aug 29;12(14):6273-6290. (PMID: 36168626)
    • Grant Information:
      210000-581835 the Qiantang Scholars Fund in Hangzhou City University; 2024YPT05 the Yuyao Science and Technology Program
    • Contributed Indexing:
      Keywords: CAR-T immunotherapy; Cancer-specific exons; Pediatric tumors; Solid tumors; Tumor microenvironment
    • الرقم المعرف:
      0 (Receptors, Chimeric Antigen)
    • الموضوع:
      Date Created: 20241113 Date Completed: 20241113 Latest Revision: 20241116
    • الموضوع:
      20241116
    • الرقم المعرف:
      PMC11556178
    • الرقم المعرف:
      10.1186/s12967-024-05861-w
    • الرقم المعرف:
      39533264